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Simple Summary: Access to molecular cancer treatments outside of clinical trials is limited and
the benefit of molecular-guided, individualized patient care in patients with cancer progression
after standard treatment is unclear. We here present the four-year experience of one of Europe’s
first Molecular Tumor Boards and show that precision oncology in the era of affordable, extended
genetic and phenotypic tumor profiling is feasible and effective for a small but relevant proportion
of advanced cancer patients. We performed a comprehensive analysis of clinical follow-up data
and report our workflow optimizations and upscaling processes. These could help other centers
to establish similar structures to support molecular-guided treatment for patients with limited
therapy options.
Abstract: Molecular precision oncology faces two major challenges: first, to identify relevant and
actionable molecular variants in a rapidly changing field and second, to provide access to a broad
patient population. Here, we report a four-year experience of the Molecular Tumor Board (MTB) of
the Comprehensive Cancer Center Freiburg (Germany) including workflows and process optimiza-
tions. This retrospective single-center study includes data on 488 patients enrolled in the MTB from
February 2015 through December 2018. Recommendations include individual molecular diagnostics,
molecular stratified therapies, assessment of treatment adherence and patient outcomes including
overall survival. The majority of MTB patients presented with stage IV oncologic malignancies
(90.6%) and underwent an average of 2.1 previous lines of therapy. Individual diagnostic recommen-
dations were given to 487 patients (99.8%). A treatment recommendation was given in 264 of all
cases (54.1%) which included a molecularly matched treatment in 212 patients (43.4%). The 264 treat-
ment recommendations were implemented in 76 patients (28.8%). Stable disease was observed in
19 patients (25.0%), 17 had partial response (22.4%) and five showed a complete remission (6.6%). An
objective response was achieved in 28.9% of cases with implemented recommendations and for 4.5%
of the total population (22 of 488 patients). By optimizing the MTB workflow, case-discussions per
session increased significantly while treatment adherence and outcome remained stable over time.
Our data demonstrate the feasibility and effectiveness of molecular-guided personalized therapy for
cancer patients in a clinical routine setting showing a low but robust and durable disease control rate
over time.
Keywords: personalized cancer medicine; precision oncology; molecular profiling; molecular tu-
mor board; targeted therapies; combination therapies; cancer progression; cancer genetics; cancer
molecular biology; cancer immunotherapy
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1. Introduction
Oncology evolves as the most innovative field in medicine; it was responsible for
28 FDA drug approvals from 2018 to 2019, a rapid expansion of the anti-cancer drug
repertoire comprising numerous targeted and immunotherapies [1,2]. For the first time,
approvals have been granted to tumor-agnostic drugs including pembrolizumab for mi-
crosatellite instability-high (MSI-H), mismatch repair deficient (MMRd), or tumor muta-
tional burden-high (TMB-H) metastatic tumors [3–5] and larotrectinib for malignancies
harboring neurotrophic receptor tyrosine kinase (NTRK) gene fusions [6]. These approvals
highlight the increasing therapeutic significance of molecular and genetic testing in on-
cology. After initial trials failed to demonstrate a clear benefit [7–10], numerous studies
and reports now support the feasibility and the effectiveness of molecular precision oncol-
ogy [11–17]. Despite these advances in tailored diagnostic and therapy, cancer remains the
second leading cause of death globally, accounting for over 9 million deaths world-wide in
2018 [18].
The large number of available cancer treatments and clinical trials in combination with
increasing accessibility of affordable extended molecular tumor profiling offer numerous
new therapy options, especially for patients who have failed standard-of-care treatment.
Furthermore, the growing knowledge of predictive biomarkers and the understanding
of treatment resistance mechanisms rapidly change treatment paradigms. To keep pace
with the dynamic field of personalized precision oncology and to provide cancer patients
state-of-the-art molecular diagnostics and treatment recommendations, we established a
Molecular Tumor Board (MTB) at the University Medical Center Freiburg Comprehensive
Cancer Center in March 2015. Here, we report a broad four-year analysis showing patient
characteristics, diagnostics and therapy recommendations, adherence, and clinical outcome
measurements. Following and extending the report of our proof-of-concept study in
2018 [19], our most recent analyses focus on structural and organizational improvements
that enabled us to triple the annual cases while confirming that clinical actionability of
molecular targets translates into improved patient outcomes.
2. Materials and Methods
2.1. MTB Organization and Patients
The MTB was founded in March 2015 and comprises a multidisciplinary team of
physicians with molecular cancer expertise from more than 16 departments and experts
from molecular pathology, molecular biology, and medical bioinformatics. There are no
formal inclusion or exclusion criteria for the presentation of patients to the MTB. Thus, it is
open for all cancer patients with the intention to focus on those who lack standard treatment
options or suffer from rare tumors. All patients discussed from March 2015 to December
2018 and treated on site (n = 488) were included in this retrospective, single-center analysis.
Patients are registered via an online system by the treating physician, who is responsible
for the initial clinical case presentation (Supplementary Figure S1). Recommendations for
molecular analyses are given after the first case presentation according to entity-specific
and entity-independent diagnostic standard operation procedures (SOP, Supplementary
Procedures), that are regularly updated. Treatment recommendations are given upon
interdisciplinary discussion according to results of molecular analyses, which are presented
by the pathology- and bioinformatics-team at the second case presentation and include
levels of molecular evidence (Supplementary Table S1). This trial was approved by the
local institutional review board of the Medical Center—University of Freiburg (protocol
code 369/19). All patients gave written informed consent.
2.2. Molecular Diagnostics
The MTB determines patient tissue sampling for molecular pathology analyses or
recommends re-biopsies if necessary. All routine molecular analyses (RMA) are performed
using nationally certified tests in the accredited laboratories of the Institute for Surgical
Pathology. These include immunohistochemistry (IHC) (comprising an immuno-oncology
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(IO)-panel, mismatch repair deficiency (MMRd)-testing, NTRK-testing, and individual
biomarkers), in situ hybridization, microsatellite instability (MSI)-testing, and targeted
next generation sequencing (tNGS; Supplementary Procedures). The IO-panel includes
IHC against CD3, CD4, CD8, PD1, and PD-L1. Scoring was performed by evaluating the
combined positivity score (CPS), tumor proportion score (TPS), and the immune cell (IC)
score [20]. MSI-testing is performed by microsatellite analysis using either the standard
panel of two mononucleotide (BAT-25, BAT-26) and three dinucleotide (D2S123, D5S346,
and D17S250) [21,22] or using a commercial test (Promega, Walldorf, Germany) of five
monomorphic mononucleotide (BAT-25, BAT-26, MONO-27, NR-21, and NR-24) repeat
markers and two polymorphic pentanucleotide (Penta C and Penta D) for additional qual-
ity control [23]. NTRK-testing is performed with IHC (NTRK-A, B, and C) and/or by
NTRK1/2/3-RNA-Fusion hybrid-capture NGS analysis. Extended genetic analysis (EGA)
includes whole-exome sequencing (WES) and RNA sequencing (RNA-Seq) and were per-
formed using mostly formalin-fixed paraffin-embedded (FFPE) tissue (90 of 104 patients;
86.5%) or fresh-frozen samples (14 of 104 patients; 13.5%). WES is performed on DNA
extracted from micro-dissected tumor tissue and complementary germline DNA from
peripheral blood or healthy tissue to distinguish germline from somatic variants. The
lowest tumor cell content was 10%. After quality control and trimming with Trimmo-
matic [24], variant calling is performed with VarScan2 [25,26] and subsequent false positive
filtering. Only non-silent variants detected with a variant allele frequency (VAF) greater
than 10% and reported with a population frequency less than 0.1% (MAF, minor allele
frequency) in the Genome Aggregation Database (gnomAD) [27] are reported. Single
nucleotide variations (SNVs) and small insertions and deletions (InDels) are classified
according to ClinVar [28], InterVar [29], COSMIC [30], dbSNP [31], cancer hotspots [32,33],
drug–gene interaction (DGIdb) [34], and functionally annotated according to the dbNSFP
database [35,36] which contains 37 prediction and nine conservation scores. Mutation
Signature Analysis is performed with the R/Bioconductor [37,38] package YAPSA [39] and
the COSMIC signatures (v2). Copy number alteration analysis is performed using Control-
FREEC [40,41]. TMB was calculated as the number of non-silent somatic mutations divided
by the number of targeted regions in megabases and was only assessed for WES data.
Tumor samples harboring more than 10 mutations per megabase were defined as TMB-H
in accordance with the FDA approval of pembrolizumab for TMB-H solid tumors [5].
The BRCAness-score was calculated as the percentage of the AC3-signature in relation to
all other mutational signatures classified by the YAPSA-package [39]. RNA fusions are
identified with FusionCatcher [42] and the STAR aligner [43] is used to align and infer
the gene expression level. The repertoire of tNGS-panels includes a hotspot eight-gene
panel (Illumina, San Diego, CA, USA), a 15 gene panel (Supplementary Table S2), a hotspot
48-gene panel (TruSeq Amplicon Cancer Panel, Illumina) [44], a BRCA1/2 panel (Illumina),
and a 54-gene myeloid panel (TruSight Myeloid Sequencing Panel, Illumina). Analyses are
performed on tumor tissue only and are processed with the Illumina pipeline. Variants
are additionally classified and reported to the entity experts according to MAF, cancer
hotspots, COSMIC, dbSNP, and Condel [45] similar to variants detected in WES. Variants
not comprised in the COSMIC- or cancer hotspots-database were categorized as “not
annotated”. Their predicted clinical relevance was assessed by the variant characteristics
mentioned above and literature research done by the entity experts.
3. Results
From March 2015 to December 2018, a total of 488 patients were discussed in the MTB
with 1072 individual case presentations and an average of 2.2 discussions per patient. Dur-
ing 95 board meetings, an average of 16 clinicians from up to 16 departments and experts
in molecular pathology, molecular biology, and medical bioinformatics participated in the
sessions. By implementing entity-specific diagnostic SOP (Supplementary Procedures) in
2017, the number of cases per MTB-session (90 min) tripled from an average of 5.8 in 2015
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to an average of 19.7 in 2018. The median turnaround time from initial case presentation to
first treatment recommendation was 42 days.
3.1. Patient Characteristics
Median age at first MTB presentation was 54 years (range 1–88 years) with a similar
distribution between females (47.1%) and males (52.9%). An overview of the patient
characteristics is shown in Table 1. The vast majority of patients suffered from solid tumor
malignancies (n = 470; 96.5%) in metastatic stage (n = 383; 78.5%). The most frequent tumor
categories were lower gastrointestinal tract (n = 68; 13.9%), pancreas (n = 50; 10.2%), and
central nervous system (n = 45; 9.2%). The median of previous lines of therapies was 2.1
(range 0–12) including a significant number of heavily pretreated patients that had received
more than three prior therapies (n = 79; 16.2%). Although there were no formal inclusion
and exclusion criteria, referral to the MTB was mostly initiated because of progression to
standard of care treatment (n = 381, 78.1%) or rare tumor entities (n = 51; 10.5%).






Median Age 54 range (1–88)
Patients with Solid Tumors: Stage at
Presentation
470 (96.5)
Metastatic Disease 383 (81.5)
Localized Disease 86 (18.3)
Complete Remission 1 (0.2)
Tumor type
Lower GI tract 68 (13.9)
Pancreas 50 (10.2)
Upper GI tract 42 (8.6)
Central nervous system 45 (9.2)
Unknown Primary Site 37 (7.6)
Hepatobiliary 30 (6.1)
Thyroid 30 (6.1)
Soft tissue and bone 37 (7.6)
Gyn (others) 18 (3.7)









Previous Lines of Therapy 2.05 (0–12)
0 66 (13.6)
1 152 (31.2)




Progression to standard of care treatment 381 (78.1)
Rare Tumor 51 (10.5)
Young Age 29 (5.9)
Unknown Primary Site 20 (4.1)
Other 7 (1.4)
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3.2. Molecular Diagnostic Testing
Diagnostic recommendations were given to all but one patient (n = 487, 99.8%), who
was diagnosed with Burkitt lymphoma and referred to the lymphoma board. Based on
regularly updated diagnostic SOP we recommended both entity-specific as well as entity-
independent tests. The latter includes MSI-, MMR-, IO-panel-, and NTRK-testing. Almost
all patients received at least one recommendation for RMA (n = 485, 99.4%), whereas more
than one third was recommended to undergo EGA (n = 183, 37.5%; Table 2). Overall, 615
of 762 diagnostic recommendations (80.7%) were pursued. Common causes for lack of
implementation were technical reasons (i.e., lack of appropriate tumor tissue for RMA or
insufficient isolation of tumor DNA for EGA; 44.9%), medical reasons (17.7%), or patient








No treatment recommendation 224 (15.9)
Conditional treatment recommendation 58 (4.1)
Patients with diagnostic recommendations 487 (99.8)
Routine molecular analysis 485 (99.4)
Extended genetic analysis 183 (37.5)
Rebiopsy 40 (5.2)
Other 14 (1.8)
Patients with Treatment recommendations 264
Not implemented 188 (71.2)
Implemented 76 (28.8)
Stable disease (off-label) 19 (13) (25.0)
Partial response (off-label) 17 (12) (22.4)
Complete remission (off-label) 5 (5) (6.6)
Disease control rate (off-label) 41 (30) (8.4)
The majority of implemented RMA (n = 3550) were IHC (n = 2599), tNGS-panels
(n = 412), and in situ hybridizations (n = 227; Supplementary Table S3). The most frequently
used tNGS assay was a 48-gene panel (n = 221) that identified a total of 502 COSMIC
annotated mutations (Figure 1A, Supplementary Data 1). The top five mutated genes
were APC, TP53, ATM, SMAD4, and ERBB4. Variants with direct therapeutic implications
(n = 343) were called using the OncoKB [46] database and were categorized as potentially
drug-sensitizing mutations including BRAF, IDH1, KIT, and PIK3CA or drug-resistance
variants in KRAS, NRAS, and KIT.







































Figure 1. Results of sequencing: (A) The bar plot depicts the number of sequence variants detected in tumor DNA using the 48-gene panel for 221 patients. Colors indicate non-targetable
COSMIC- (grey) and non-targetable hotspot mutations (blue). Actionable variants are shown in green (drug-sensitizing) and red (drug-resistance) based on the OncoKB classification.
(B) The heatmap depicts the 50 most frequently mutated somatic genes of the 104 patients analyzed by whole-exome sequencing (WES). The colors indicate tumor entities, type of mutation,
tumor mutational burden and BRCAness-score (= AC3−signature). Only mutations with a variant allele frequency greater than 10% and a minor allele frequency less than 0.1% were
considered. (C) The bar diagram depicts all mutations that were annotated as targetable by the OncoKB classification. The colors indicate tumor entities. (D) The heatmap depicts copy
number variations of the most frequently affected oncogenes. The colors indicate tumor entities and the total copy number per oncogene. Gene copy number gains that were annotated as
targetable by the OncoKB algorithm are depicted in red.
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EGA was recommended to 183 patients (37.5%; WES and/or RNA-seq: n = 180; RNA-
seq only: n = 3), especially to young individuals (<50 years), patients with rare tumors or in
cases in which RMA did not identify a therapeutic target. Re-biopsies were recommended
to 40 patients (8.2%) in cases in which adequate tumor material was not available (i.e., low
amount of tissue, low tumor cell content, long time from biopsy to presentation). WES was
performed for 104 patients (21.3%) and revealed 10,484 mutations, including 2064 COSMIC-
annotated (thereof 64 in hotspot regions) and 8420 unknown somatic variants (Figure 1B,C,
Supplementary Data 2). According to TARGET or DGIdb, 1987 mutations were classified
as actionable. The more clinically relevant OncoKB classification revealed 53 targetable
mutations (Figure 1C and Supplementary Figure S2A). An overview of the most commonly
mutated genes, including the corresponding entities, is shown in Figure 1B. Cancer genes
that were mutated in at least three cases (n = 19) are depicted in Supplementary Figure
S2B. The top five mutated cancer genes were TP53, KRAS, APC, BRAF, and AR. The
bioinformatics pipeline further reported copy number variations (CNV) from oncogenes
(Figure 1D) and tumor suppressor genes (Supplementary Figure S2C). Of special interest
were high copy number gains of oncogenes (>7; dark red in Figure 1D) that were annotated
according to the OncoKB database and represent possible actionable targets (Gene names
in red in Figure 1D). We also assessed TMB as a surrogate for neoantigen driven tumor
immunogenicity and as a predictive marker of response to immune checkpoint blockade
(ICB)-based therapy (Figure 1D). TMB-H (>10 mutations per megabase) was found in 10 of
104 sequenced patients (9.6%). Additionally, we determined mutational signatures that
reflect different exogenous and/or endogenous mutational processes that cause somatic
mutations in cancer (Supplementary Figure S2D) [47,48]. Of importance to the MTB, the
AC3-signature reflects defects in homologous recombination repair mechanisms known
from BRCA-deficient tumors [47–49]. Following the concept of synthetic lethality, tumors
harboring this BRCAness phenotype might be susceptible towards poly-(ADP)-ribose
polymerase inhibitors (PARPis) or DNA damaging agents [50–52]. A positive BRCAness-
score (>20%, based on NCT03127215) was seen in 29 of 104 sequenced patients (27.9%;
Figure 1B).
3.3. Treatment Recommendations
The interpretation and interdisciplinary discussion of diagnostic results led to a treat-
ment recommendation in 264 of 488 patients (54.1%). A total of 367 treatment recommen-
dations were given to these 264 patients. The majority of recommendations were off-label
treatments (n = 248 of 367; 67.6%) and referral to accessible clinical trials (n = 67; 18.3%).
In addition, recommendations comprised 52 in-label therapy-options (14.2%). The most
commonly recommended treatment categories were single-agent targeted therapy (TT,
n = 159 of 367; 43.3%), immune checkpoint blockade (ICB, n = 102; 25.1%), and combination
therapies (CT; n = 92; 25.1%; Supplementary Table S3). To evaluate the clinical utility of
molecular and genetic alterations, the MTB recommendations were categorized according
to levels of molecular evidence (Supplementary Table S1). These were based on our initial
definition [19] and were refined and harmonized for use in MTBs in Germany [53]. The
majority of recommendations were based on molecular evidence from clinical trials or
cohorts in the same (m1; n = 166 of 367; 45.2%) or in a different tumor entity (m2; n = 92;
25.1%) while a smaller fraction was based on molecular in vitro or in vivo evidence (m3;
n = 101; 27.5%) or a biologic rationale (m4; n = 4; 1.1%; Supplementary Table S3).
Treatments were implemented in 76 of the 264 patients receiving a therapy recom-
mendation (28.8%). The distribution of recommended therapies by type of treatment,
implementation status and outcome is shown in Figure 2. Implemented off-label treat-
ment recommendations were based on results of RMA (tNGS: n = 18 of 82; 22.0%; IHC:
n = 17; 20.7%) and EGA (n = 12, 14.6%, Supplementary Table S4). Common causes for
non-implementation were conditional recommendations designated to the future and not
captured during the course of study (i.e., patients with stable disease under current therapy;
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n = 44 of 188; 23.4%), medical reasons (n = 43; 22.9%), and patient death (n = 35; 18.6%,
Supplementary Table S4).
Patients discussed (n = 488) 
Patients with rationale for single agent TT 
(n = 102) 
Patients with rationale for drug combination 
(n = 70) 
No actionable target (n = 224) 
In-label chemotherapy (n = 7) 
Not implemented (n = 77) 
 
a) TKI/SM (n = 63) 
b) AB (n = 7) 
c)  Others (n = 7) 
 
• In future (n = 21) 
• Medical reason (n = 16) 
• Patient death (n = 14) 
• Other (n = 8) 
• Loss to FU (n = 7) 
• Patient will (n = 6) 
• Declined by company 
(n = 3) 
• Study screening failure 
(n = 2) 
Implemented (n = 25) 
 
a) TKI/SM (n = 19) 
b) AB (n = 3) 
c)  Other (n = 3) 
 
• Off-label (n = 15) 
• In-label (n = 8) 
• Study (n = 2) 
Not implemented (n = 49) 
 
a) ICB + X (n = 16) 
b) TT (n = 19) 
c)  Ch + AB (n = 4) 
d) Combi other (n = 10) 
 
• In future (n = 11) 
• Medical reason (n = 13) 
• Patient death (n = 11) 
• Other (n = 5) 
• Loss to FU (n = 3) 
• Patient will (n = 2) 
• Declined by health 
insurance (n = 0) 
• Study screening failure 




a) ICB + X (n = 8) 
b) TT (n = 4) 
c)  Ch + AB (n = 6)  
d) Combi other (n = 3) 
 
• Off-label (n = 15) 
• In-label (n = 4) 
• Study (n = 2) 
Outcome 
 
• PR (n = 3)  
• SD (n = 8) 
• PD (n = 10) 




• CR (n = 1) 
• PR (n = 5)  
• SD (n = 5) 
• PD (n = 8) 
• Lost to FU or NE 
(n = 2) 
• PR (n = 2)  
• SD (n = 1) 
Patients with rationale for mono ICB 
(n = 83) 
Not implemented (n = 59) 
 
• In future (n = 12) 
• Medical reason (n = 13) 
• Patient death (n = 9) 
• Other (n = 7) 
• Loss to FU (n = 4) 
• Patient will (n = 8) 
• Declined by health 
insurance (n = 5) 
• Study screening failure 




• Off-label (n = 16) 
• In-label (n = 6) 
• Study (n = 2) 
Outcome 
 
• CR (n = 3) 
• PR (n = 7)  
• SD (n = 4) 
• PD (n = 8) 
• Lost to FU or NE 
(n = 2) 
Off-label hormone therapy (n = 2) 
Outcome 
• SD (n = 1) 
• CR (n = 1) 
Figure 2. Flow diagram of patients discussed at the MTB. Responses were determined according to Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1.; (a–d) represent various drug categories as indicated. PR = Partial remission.
SD = Stable disease. PD = Progressive disease. ICB = Immune checkpoint blockade. TT = Targeted therapy. TKI = Tyrosine
kinase inhibitor. SM = Small molecule. AB = Antibody. ICB + X = Combination of immune checkpoint blockade with
another drug. Ch + AB = Combination of chemotherapy with an antibody. FU = Follow-up. NE = Not evaluable.
3.4. Clinical Outcome
Of the 76 patients that pursued an MTB treatment recommendation, 19 patients
experienced stable disease (SD; 25.0%), 17 a partial response (PR; 22.4%), and five achieved a
complete remission (CR; 6.6%), resulting in an overall objective response rate (ORR) of 4.5%
(22 of 488 patients) and an overall disease control rate (DCR) of 8.4% (41 of 488 patients). Of
the 41 patients with disease control, 30 received off label-treatments (30 of 488; 6.1%) and
23 received off-label treatments that were strictly based on a molecular rationale (23 of 488;
4.7%). To further validate the clinical significance of patients experiencing SD, we compared
the PFS of the previous line of therapy (PFS1) to the PFS of the treatment recommended by
the MTB (PFS2). A PFS2 to PFS1 ratio of 1.3 or higher is established as marker indicating
benefit of a molecular-guided treatment in advanced cancer patients [17,54–58]. According
to the modified progression-free survival ratio (mPFSr) [59], we excluded three patients
from this analysis. One patient was removed after converting PFS1 times below two
months into modified PFS1 intervals of two months to adjust for false positives, and two
patients were excluded because PFS1 was not assessable. Of the remaining 20 patients,
17 fulfilled the criteria receiving strictly molecular-matched off-label treatment, and if SD,
with mPFSr ≥ 1.3, resulting in an adjusted DCR of 3.5% (17 of 488 patients). Detailed
clinical information of patients achieving at least stable disease and receiving off-label
therapies between March 2017 and December 2018 (n = 16) are shown in Table 3. The
corresponding data for 14 patients who had achieved at least stable disease between
March 2015 and February 2017 were reported previously [19]. Two patients experiencing
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exceptional treatment response are presented in two case reports, medullary thyroid
cancer and pleomorphic xanthoastrocytoma, in Supplementary Figures S3 and S4 and Case
reports [60,61].
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Response ongoing.
Forty-one out of 488 patients showed disease control under the recommended treatment. Progression free survival (PFS1, PFS2) was
determined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Median PFS2 (53 weeks; range 6–238 weeks)
was significantly longer than median PFS1 (16 weeks; range 3–16 weeks; p = 0.003). Here we list the yet unpublished off-label responders
(16 patients) that were discussed between March 2017 and December 2018. Relevant diagnostic results leading to a board recommen-
dation, level of evidence (EL), label (L), treatment response (R), progression free survival (PFS1, PFS2), progression free survival ratio
(PFS2/PFS1 = PFSr) and outcome are shown. PFS1 and PFSr could not be evaluated for four patients since they did not receive a prior
systemic treatment. PR: partial response. SD: stable disease. n.a.: not applicable. CUP: cancer of unknown primary. IO-Panel: Immuno-
oncology panel. TPS: Tumor Proportion Score. CPS: Combined positive score. IC-Score: Immune cell score. TILs: Tumor infiltrating
lymphocytes. CNV: Copy number variation. PXA: Pleomorphic xanthoastrocytoma.
In order to assess the impact of the MTB on overall survival (OS) we used a Kaplan–
Meier estimate to analyze survival of patients from first MTB presentation. To reduce
possible confounders, we only included patients with stage IV malignancies (n = 340)
and excluded patients who had died prior to therapy initiation (n = 53) or who showed
disease control at the time of recommendation (n = 37). We observed a significant OS-
benefit in 73 patients who pursued the recommended therapy (18 months; 95% CI, 11 to
30 months), compared to 100 patients who did not implement the treatment recommenda-
tion (OS = 8 months; 95% CI, 7 to 12 months; p = 0.008) or 167 patients who did not receive
a recommendation (OS = 8 months; 95% CI, 7 to 12 months; p = 0.003).
4. Discussion
In this retrospective case series, we analyzed a total of 488 patients with mostly stage IV
malignancies (n = 442; 90.6%), who were consecutively referred to a single institution MTB
between March 2015 and December 2018, mostly because of progression to standard of care
treatment (78.1%) or rare tumor entities (10.5%, Table 1). Based on entity-specific and entity-
independent diagnostic SOP, we recommended individual molecular tests to 99.8% of the
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patients (n = 487) with a high implementation rate of 80.7% for diagnostic recommendations.
The results enabled the MTB to issue individual treatment recommendations to more than
half of the patients (n = 264; 54.1%) of which almost one third (n = 76 of 264; 28.8%) received
the respective therapy. The overall ORR to recommended therapies was 4.5%, and the
overall DCR was 8.4%. Other MTBs reported similar rates of treatment recommendations
and implementation as well as DCRs: Baltimore [14] (24%, 16%, and 9%), Cleveland [15]
(49%, 11% and 3.2%) and a recent report from Vienna [16] (54%, 23% and n.a., respectively).
An ORR of 4.5% for a study in the oncology field is low. However, this number must be
put into perspective given the challenging patient cohort. Most patients had metastatic
cancer and were beyond standard of care treatment. Non-implementation of treatment
was often related to patient death (18.6%) or bad general condition (7.5%). We therefore
believe that the low percentage of patients experiencing disease control still represents a
substantial proportion profiting from the MTB, given the challenging clinical situation of
these patients.
We believe that our approach of SOP-driven and stepwise molecular diagnostics is
time- and cost-effective as the median turnaround time from the first MTB to the first treat-
ment recommendation was 42 days and the majority of recommendations did not require
additional expensive and time-consuming EGA (85.4%). Treatment recommendations were
based on EGA-results in 14.6% of patients. This included patients who received upfront
WES or RNA-seq, i.e., patients with carcinoma of unknown primary, rare malignancies, or
young patients. If the patient’s general condition afforded sufficient time to complete the
analysis, EGA was also performed as a second diagnostic step when RMA did not identify
any molecular target. Underlining the clinical effectiveness of treatment recommendations,
patients with stage IV malignancies who received recommended treatments showed a
significant benefit in OS (18 months; 95% CI, 11 to 30 months), which is encouraging com-
pared to patients without recommendation (8 months; 95% CI, 7 to 12 months; p = 0.003) or
lack of implementation (8 months; 95% CI, 7 to 12 months; p = 0.008). However, despite the
attempt to reduce imbalances between subgroups the validity of this survival analysis is
limited. Due to the low sample size, implementation of propensity score matching between
cohorts was not possible, and thus potential confounders are beyond control.
Compared to our initial proof of concept report including 198 patients in 2018 [19] we
were able to maintain constant rates of treatment recommendations (55.1% vs. 52.5%), while
the treatment implementation rate remained relatively low (28.8% vs. 31.7%). Common
causes for non-implementation were medical reasons (22.9%) and patient death (18.6%).
We hypothesize that a streamlined workflow to grant access to off-label treatments using
consented criteria would allow a higher proportion of patients to receive the recommended
treatment in due time. Therefore, the MTB will in the future provide applications to health
care providers. These will be sent with the corresponding treatment recommendation to the
treating physician. Compared to our previous analysis, patient outcomes remained stable
over time (DCR 7.6% vs. 9.6%), while case numbers per 90-min MTB meeting increased sig-
nificantly (18.0 vs. 8.1). The efficiency of the MTB workflow was improved by assignment
of patients to an entity-expert at least four days prior to first discussion, establishment
in 2017 of a regular process to update diagnostic SOP, generation of automated reports
for WES data within two days after receiving the raw sequencing data, communication of
detailed diagnostic results to the entity-expert prior to MTB discussion, and the preparation
of draft recommendations by the entity-expert to discuss and consent during the meeting
(Supplementary Figure S1).
Our report is in line with prospective precision oncology trials that demonstrated
the impact of molecular driven therapies on patient outcome [11–13,63] underlining the
importance of upscaling MTBs in order to facilitate treatment access to cancer patients who
lack standard treatment options. A survey from van der Velden et al. revealed that in the
Netherlands < 50% of hospitals and only 5% of non-academic hospitals had access to an
MTB in 2017 [64]. To address this medical need, we opened the MTB to patients treated by
external hospitals and private practice oncologists in June 2016. External referrals to the
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MTB increased from an average of 1.1 patients per session in 2016 to 1.7 in 2018. To further
grant MTB-access to more cancer patients and to reduce discrepancies in care, related to
diverse bioinformatics workflows [65] and heterogeneous standards for interpretation of
molecular aberrations [66], the comprehensive cancer centers of southwest Germany up-
scaled referrals and harmonized their workflows and SOPs in 2020. This network initiative
(Zentrum für Personalisierte Medizin, ZPM, Baden-Württemberg, Germany) also estab-
lished a digital cloud that collects molecular diagnostic results and clinical follow-up data.
This data will be used to identify both positive and importantly also negative correlations
between molecular biomarker-driven therapies and outcomes. Accessible and effective
drugs or clinical trials may therefore be identified easier and faster. Health care providers
expressed an intrinsic interest to support and fund the establishment of the German ZPM-
network since the increasing number of off-label requests from oncologists [67] will be
streamlined through specialized MTBs allowing a harmonized and fast decision process
with evidence based recommendations (Supplementary Table S1).
An important goal of the MTB is to improve access to available and accessible molecu-
larly stratified trials for cancer patients. In close collaboration with the early clinical trial
unit (ECTU) on site, the Freiburg MTB hosts a large number of innovative phase I and II clin-
ical basket studies. Potential MTB-candidates are pre-screened at the earliest convenience
for trials available on- and off-site to provide rapid access to these attractive molecular
trial options. Compared to our initial report in 2018 we were able to increase the trial
recommendation rate from 12.5% to 20.2%, a high rate comparable to recently published
reports from Paris [68] (13.2%) and London [69] (20%). Based on informative MTB patients
with exceptional responses, we were able to develop and initiate two investigator-initiated
early clinical trials, ATLEP (DRKS00013336) and SORATRAM (DRKS00015849).
One of the major challenges of an MTB is to keep up with the dynamic field of
predictive biomarkers for targeted and immuno-oncology treatments. For instance, the
era of ICB opened up a new field of research to identify patients who would benefit
from treatment outside the approved indications such as melanoma, lung, and renal cell
carcinoma. In our cohort, established predictive biomarkers like expression of PD-L1 [70],
MSI [71,72] and TMB [73–75] directed off-label ICB-mono or ICB-combination treatment
recommendations in 108 cases (22.1%) of which 28 (25.9%) received therapy, resulting in
a subgroup DCR of 57.1% (16 of 28 patients). Treatment response was associated with a
positive IO-panel in 11 of 28 cases (39.3%) versus a negative IO-panel in five patients (17.9%;
Supplementary Table S5). Interestingly, all seven patients with anaplastic thyroid cancer
had a positive IO-panel with a TPS-Score ≥ 5, suggesting immune hot tumors. Indeed, all
but one patient experienced disease control including two complete remissions. Of note,
the positive results of the Keynote-158 study [71,73] led to a tumor-agnostic FDA-approval
for pembrolizumab in June 2020 [5] reflecting one essential aspect of the MTB, namely, to
provide patients early access to promising drugs not yet approved.
The identification of potential novel biomarker-driven drug treatments and therapy
studies relies heavily on the expertise and knowledge of the MTB panel members. Hence,
they face the challenge of critically examining the large, fast-moving literature of precision
oncology to provide patients with the best possible molecular advice. Therefore, our
interdisciplinary team is divided into entity-experts with strong expertise in molecular
oncology for specific entities, molecular pathologists, medical bioinformaticians, and
translational scientists.
A multitude of anti-cancer drug combination therapies have been introduced by the
FDA since the initial approval of trastuzumab and pertuzumab in combination with the
chemotherapeutic agent docetaxel in 2012 [76], increasing the probability and magnitude
of treatment response as well as circumventing primary or acquired escape mechanisms.
Accordingly, recommendations for combination therapies have increased from 18.3% to cur-
rently 28.5% since our first report in 2018. A total of 70 patients (14.3%) were recommended
a combination therapy of which 21 (30%) received the respective treatment resulting in a
subgroup DCR of 52.4% (11 of 21 patients, Figure 2). Of note, none of the implemented
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treatments were discontinued due to toxicity. Again, this indicates the success, but also the
increasing complexity of modern anti-cancer therapy, necessitating structured molecular
diagnostics and treatment recommendations.
5. Conclusions
This retrospective analysis of 488 patients included in the MTB Freiburg from 2015 to
2018 demonstrates a successful transition from proof-of-concept to routine clinical service.
Despite significant upscaling processes, we confirm that molecular-guided precision oncol-
ogy remains effective for a small but relevant proportion of advanced cancer patients that
are beyond standard-of-care treatment.
Supplementary Materials: The following are available online at https://www.mdpi.com/2072-669
4/13/5/1151/s1, Supplementary Figure S1: Revised workflow of the MTB, Supplementary Figure S2:
Extended results of whole exome sequencing, Supplementary Figure S3: Targeting RET in medullary
thyroid cancer, Supplementary Figure S4: Targeting BRAF/MEK in pleomorphic xanthoastrocytoma.
Case reports: Successful molecularly guided therapy through the MTB. Supplementary Procedures:
Diagnostic standard operation procedures. Supplementary Table S1: Levels of evidence, Supple-
mentary Table S2: Details of tNGS gene panels, Supplementary Table S3: Diagnostic and treatment
recommendations, Supplementary Table S4: Details of treatment recommendations, Supplementary
Table S5: Immuno-oncology panel and ICB-treatment response.
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